Table 2.
Licenseda immunoglobulin products for human passive immunisation.
| Disease/pathogen source | Immunoglobulin product | |
|---|---|---|
| Allograft rejection | Equine or rabbit anti-thymocyte IgG | |
| Anthrax | Monoclonal antibody (Raxibacumab and Obiltoxaximab), immune human Ig (Anthrivig™) | |
| Snakebite | Black widow spider | Equine Ig |
| Scorpion | Equine F(ab’)2b | |
| Rattlesnakec | Ovine Fabb | |
| Botulism | Type A and B | Human Ig |
| Type A-G | Equine Ig | |
| Chickenpox, shingles (Varicella-Zoster virus) | Immune human Igd | |
| Cytomegalovirus | Immune human Ig | |
| Digoxin toxicity or overdose | Ovine Fabb | |
| Diphtheria | Specific equine Ig | |
| Hepatitis A, measles | Pooled human Ig | |
| Hepatitis B | Immune human Ig | |
| Primary Humoral Immunodeficiency, Immune Thrombocytopenic Purpura, (prevention of) allogeneic bone marrow transplantation rejection, Guillain Barré syndrome, Kawasaki disease | Pooled human IgGd | |
| Rabies | Immune human Ig | |
| Respiratory syncytial virus induced disease | Monoclonal antibody (Palivizumab) | |
| Smallpox (Vaccinia virus) | Immune human Ig | |
| Tetanus | Immune human Igd | |
a
Licensed by either FDA or EMEA.
b
Fab/F(ab’)2 denotes products of IgG molecules after enzymatic digestion still capable of binding to antigen in question.
c
Rattlesnake antivenom covers following species: North American snake venoms: Crotalus atrox (Western Diamondback rattlesnake), Crotalus adamanteus (Eastern Diamondback rattlesnake), Crotalus scutulatus (Mojave rattlesnake), and Agkistrodon piscivorus (Cottonmouth or Water Moccasin).
d
Pooled human IgG (i.e. IVIG) can also be used.